Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT-TN: FMD Plus Chemo-immunotherapy in TNBC
NCT07378306Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Primary endpoint: Pathological Complete Response Rate. Started Mar 2026; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07378306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07378306.